BMS 986172
Alternative Names: BMS-986172Latest Information Update: 28 Jul 2025
At a glance
- Originator Bristol-Myers Squibb
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Jul 2025 No recent reports of development identified for preclinical development in Unspecified in USA
- 15 Jun 2021 Bristol-Myers Squibb plans a phase I trial (In volunteers) in USA (NCT04926051)
- 14 Jun 2021 Preclinical trials in Unspecified in USA (unspecified route), prior to June 2021